SGLT-2 inhibitor and/or incretin mimetic as an add-on?

Nowadays, the choice of drug therapy is no longer based solely on the_{baseline HbA1c level}, but also on risk factors or comorbidities such as heart failure, kidney disease, or obesity. Due to their additional cardiorenal benefits, SGLT-2 inhibitors or incretin mimetics are recommended as add-ons to metformin for many people with type 2 diabetes. Furthermore, it has been shown that additive effects can be achieved by combining SGLT-2 inhibitors and incretin mimetics. The fact that a dual GLP-1/GIP agonist has now also become established in clinical practice represents a further optimization of treatment options.